relationship between the results of HLA-matched in (PBSC) unrelated donor peripheral blood stem cell transplantation has not yet been established. 1933 unrelated received high-resolution HLA typing for you and received between PBSC transplantation from 2006 to 1999 for chronic myeloid leukemia acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome The study of a pair of donors and recipients, the overall HLA-,-B,-C 1, DQA1 and DQB1,-DRB, was included in the analysis. And according to the characteristics of transplant patients and were compared between a pair of HLA-mismatched and HLA-matched results. HLA-A, B,-C compared to (vs. 56% 47%) 8.7 HLA fit pair, was associated with increased survival rate after one year matching one allele (8.8 min)-DRB and. By using the 8.8 HLA fit patient as (N = 1243) base, (relative risk [RR], (N = 189) is associated with a 1.36,95% confidence interval leukemia progression-free survival significantly lower mismatch of HLA-C antigen 1.70 (RR, 1.41,95% CI, from 1.16, P = 0.0005), (RR, 1.61,95% CI treatment-related increase in the rate of death is, 1.64 1.13, P = 0.0010), risk of death , 1.25-2.8, a P = 0.0002), grade III-IV of transplantation for host disease 2.62 (RR, 1.98,95% CI, from 1.50, P <0.0001). Mismatched alleles or HLA-B antigen is associated with an increased risk of acute GVHD grade III-IV. Differences statistically significant, (N = 61), HLA antigen / allele that was not observed in HLA-C alleles HLA-(N = 136), HLA-DRB1 alleles or (N = 39), the result contradiction of (= 114 compared to N 8.8 HLA compatible pair) DQ antigen / allele. Mismatch of HLA is not associated with chronic GVHD or recurrent. HLA-C antigen mismatched unrelated PBSC donors were associated with bad results as compared with 8.8 HLA matched donor. Because, the limited power of the study of the small sample size does not allow conclusions about other contradictions.

In addition to the long patch pathway for a total correction of the special repair pathway to remove replication errors, DNA mismatches specific base. To remove thymine from G / T mispairs in DNA replication, thymine DNA glycosylase (TDG) starts from the exchange of non-pyrimidine base excision repair pathway with this. TDG is, has a strong preference for thymine CpG motif mismatched base of DNA, its role, 5 – is to tax the product of deamination of methyl cytosine. Repair in this case is related to the removal and replacement of deamination-based single. In mammalian homolog of a DNA glycosylase other can also MutY protein Escherichia coli, I have found, start the base excision repair, is considered as a mismatch repair enzyme, if. If you incorporate oxidized form of guanine opposite adenine, basis of I found that. Favorite effects I replication and found that if it is to reduce the burden on transversion mutation is a result of oxidative damage to DNA often at A/8-oxoG pairing is expected is the time. One is whether you can A / C mispairs and consumption tax by AG / adenine also purification Sonoko calf thymus seen widely.

Conditions of hereditary human associated with reduced ability to perform gap adjustment of defects in the base excision repair pathway in long patch pathway is strongly do not associated with cancer in humans. Most of the mismatch repair genes hMSH2 or hMLH mutations of germ cells associated with familial cancer susceptibility in (HNPCC) syndrome hereditary nonpolyposis colon cancer. Early onset of cancer, people of HNPCC will develop a particular cancer of the endometrium and colon. In the tumor, the HNPCC, allele mismatch repair the second, has received the body, inactivation of tumor cells, does not contain detectable long patch mismatch correction activity. Inactivation of the remaining allele is a case of initial probably has contributed to the rapid growth of the tumor definitely mutator phenotype as a result.

In a standard assay, extracts of HeLa cells or human Colo26 mouse colon tumor, fixes a possible single base mispairs any. Examples of other repair and TC / mismatch is shown in Figure Figure2.2. Mouse did not perform open repair of T / G mismatch or T / C – RH95021 cell immortality the MSH2-/ embryo-derived fibroblasts extract. Mouse cell line – this is consistent with the lack of long-patch mismatch repair pathway in MSH2 /. Unlike the mismatched A / C, was effectively corrected by that this is comparable to the mouse cell extracts and Colo26 RH95021 total and repair human HeLa of A / C and the same RH95021 cell extract. RH95021 extract is made, low maintenance of mismatch / G. / Degree of correction of the mismatch is close to the detection limit of the analysis. 20 to 30 minutes about half-time and were similar, it is very fast in the range of concentration of RH95021 Colo26 extraction mouse cell extracts and repair. Therefore, it is possible regardless of the RH95021 mouse cell MSH2 defect extraction, correction is performed and effective selection of AC / mispairs of long patch mismatch repair pathway.